Journal of Clinical Oncology, Vol 10, 452-458, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium

EJ Dropcho, SS Rosenfeld, RB Morawetz, J Vitek, M Brothers, T Gorum, S Bell, GY Gillespie, M Glantz and MS Mahaley Jr
Department of Neurology, University of Albama, Birmingham 35294.

PURPOSE: This phase II study was performed to assess the response of patients with newly diagnosed, untreated malignant gliomas (anaplastic astrocytoma [AA] and glioblastoma multiforme [GBM]) to intracarotid (IC) cisplatin. PATIENTS AND METHODS: Eligibility criteria included surgical intervention limited to biopsy only, measurable contrast- enhancing tumor, and unilateral tumor location within the vascular territory of one internal carotid artery. Patients were scheduled to receive four infusions of IC cisplatin (75 mg/m2 every 4 weeks) before beginning standard radiotherapy. Twenty-six patients were treated, and 22 were assessable for response. RESULTS: Ten patients (45%) showed a greater than 25% decrease in the enhancing tumor area before radiotherapy with stabilization or improvement of neurologic deficits, and three patients (14%) had a greater than 70% decrease in tumor area. The likelihood of response to IC cisplatin was not clearly linked to patient age, tumor histology, or pretreatment tumor size. Myelosuppression, nephrotoxicity, and ototoxicity were mild. Optic neuropathy occurred in one patient, seizures in two, and fatal postinfusion cerebral edema in one. CONCLUSION: This study design, which permits assessment of the drug sensitivity of the untreated glioma, has shown definite antitumor activity of IC cisplatin in newly diagnosed malignant glioma patients.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. L. Zuur, Y. J. Simis, P. E. Lansdaal, A. A. Hart, J. H. Schornagel, W. A. Dreschler, C. R. Rasch, and A. J. Balm Ototoxicity in a Randomized Phase III Trial of Intra-Arterial Compared With Intravenous Cisplatin Chemoradiation in Patients With Locally Advanced Head and Neck Cancer J. Clin. Oncol., August 20, 2007; 25(24): 3759 - 3765. [Abstract] [Full Text] [PDF]

				C. L. Shields, H. Demirci, B. P. Marr, A. Masheyekhi, M. Materin, and J. A. Shields Chemoreduction With Topical Mitomycin C Prior to Resection of Extensive Squamous Cell Carcinoma of the Conjunctiva Arch Ophthalmol, January 1, 2005; 123(1): 109 - 113. [Full Text] [PDF]

				M. R. Gilbert, H. S. Friedman, J. F. Kuttesch, M. D. Prados, J. J. Olson, G. H. Reaman, and S. L. Zaknoen A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy Neuro-oncol, October 1, 2002; 4(4): 261 - 267. [Abstract] [PDF]

				K. L. Chow, Y. P. Gobin, T. Cloughesy, J. W. Sayre, J. P. Villablanca, and F. Viñuela Prognostic Factors in Recurrent Glioblastoma Multiforme and Anaplastic Astrocytoma Treated with Selective Intra-arterial Chemotherapy AJNR Am. J. Neuroradiol., March 1, 2000; 21(3): 471 - 478. [Abstract] [Full Text]

				N. G. Avgeropoulos and T. T. Batchelor New Treatment Strategies for Malignant Gliomas Oncologist, June 1, 1999; 4(3): 209 - 224. [Abstract] [Full Text]

				C. L. Shields, P. De Potter, B. P. Himelstein, J. A. Shields, A. T. Meadows, and J. M. Maris Chemoreduction in the Initial Management of Intraocular Retinoblastoma Arch Ophthalmol, November 1, 1996; 114(11): 1330 - 1338. [Abstract] [PDF]